Nature Medicine
- 12, 1056 - 1064 (2006)
Published online: 3 September 2006; Corrected online: 10 November 2006 | doi:10.1038/nm1468
There is a Corrigendum (December 2006) associated with this Article.
Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosisAdriano G Rossi1, Deborah A Sawatzky1, 3, Annemieke Walker1, 3, Carol Ward1, Tara A Sheldrake1, Nicola A Riley1, Alison Caldicott1, Magdalena Martinez-Losa1, Trevor R Walker1, Rodger Duffin1, Mohini Gray1, Elvira Crescenzi2, Morag C Martin1, Hugh J Brady2, John S Savill1, Ian Dransfield1 & Christopher Haslett11
MRC Centre for Inflammation Research, Queen's Medical Research Institute, University of Edinburgh, 47 Little France Crescent, Edinburgh, EH16 4TJ, UK. 2
Molecular Haematology and Cancer Biology Unit, Institute of Child Health, Great Ormond Street Hospital for Children NHS Trust, University College London, 30 Guilford Street, London WC1N 1EH, UK. 3
These authors contributed equally to this article.
Correspondence should be addressed to Adriano G Rossi a.g.rossi@ed.ac.uk Apoptosis is essential for clearance of potentially injurious inflammatory cells and subsequent efficient resolution of inflammation. Here we report that human neutrophils contain functionally active cyclin-dependent kinases (CDKs), and that structurally diverse CDK inhibitors induce caspase-dependent apoptosis and override powerful anti-apoptosis signals from survival factors such as granulocyte–macrophage colony-stimulating factor (GM-CSF). We show that the CDK inhibitor R-roscovitine (Seliciclib or CYC202) markedly enhances resolution of established neutrophil-dependent inflammation in carrageenan-elicited acute pleurisy, bleomycin-induced lung injury, and passively induced arthritis in mice. In the pleurisy model, the caspase inhibitor zVAD-fmk prevents R-roscovitine–enhanced resolution of inflammation, indicating that this CDK inhibitor augments inflammatory cell apoptosis. We also provide evidence that R-roscovitine promotes apoptosis by reducing concentrations of the anti-apoptotic protein Mcl-1. Thus, CDK inhibitors enhance the resolution of established inflammation by promoting apoptosis of inflammatory cells, thereby demonstrating a hitherto unrecognized potential for the treatment of inflammatory disorders.
NOTE: In the version of this article initially published, the dose stated for zVAD-fmk administration was incorrect. The methods reported on page 1062 should read "Twenty-four hours after intrapleural injection of carrageenan, mice were injected i.p. with 10 mg per kg of R-roscovitine and/or 5 mg per kg of zVAD-fmk (z-Val-Ala-DL-Asp-fluoromethylketone; Bachem)". Similarly, the legend to figure 4, line 3, should read "C57/bl6 mice were treated with 10 mg per kg of R-roscovitine (i.p.) and/or 5 mg per kg of zVAD-fmk (i.p. at 4-h intervals)". We also made an error reporting the time of administration of K/Bxn serum in the legend to figure 5, line 14. This should read "Mice (n =10 in each group) were injected twice (days 0 and 2) with K/BxN serum derived from arthritic (day 60) K/BxN transgenic mice." The error has been corrected in the HTML and PDF versions of the article.
MORE ARTICLES LIKE THIS These links to content published by NPG are automatically generated.
|
